Autonomic Regulation Therapy in Heart Failure
Una Buckley1, Kalyanam Shivkumar, Jeffrey L Ardell
1Cardiac Arrhythmia Center & Neurocardiology Research Center of Excellence, UCLA David Geffen School of Medicine, 100 Medical Plaza, Suite 660, Los Angeles, CA, 90095, USA, UBuckley@mednet.ucla.edu.
Current Heart Failure Reports
|June 10, 2015
Summary
Autonomic regulation therapy (ART) offers a new approach for systolic heart failure. Understanding how device-based stimulation affects the autonomic nervous system is key to optimizing this emerging treatment.
Area of Science:
- Cardiology
- Neuroscience
- Biomedical Engineering
Background:
- Congestive heart failure (CHF) with systolic dysfunction affects millions globally.
- Current treatments for systolic heart failure have limitations.
- Autonomic nervous system (ANS) dysfunction plays a critical role in CHF progression.
Purpose of the Study:
- To review preclinical and clinical research on Autonomic Regulation Therapy (ART) for systolic heart failure.
- To explore the mechanisms of bioelectronic modulation of the ANS in heart failure.
- To highlight the importance of understanding ANS response to optimize ART.
Main Methods:
- Literature review of preclinical and clinical studies on ART.
- Analysis of device-based therapies targeting the cardiac neuronal hierarchy.
- Examination of bioelectronic modulation techniques including spinal cord, cervical vagus, baroreceptor, and renal nerve interventions.
Main Results:
- ART involves modulating the ANS via bioelectronic devices.
- Targeting specific nerves (spinal cord, vagus, baroreceptor, renal) shows potential in managing systolic heart failure.
- Understanding the mechanistic response of the ANS to stimulation is crucial.
Conclusions:
- ART is an emerging therapeutic strategy for systolic heart failure.
- Device-based modulation of the ANS holds promise for improving cardiac function.
- Further research into the mechanistic understanding of ART is essential for its advancement and optimization.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:31Regulation of Heart Rates
5.2K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
5.2K
01:22Heart Failure VI: Adjunct Therapies
599
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
599
01:30Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:25Aortic Regurgitation III: Medical Management
559
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
559